TARSTarsus Pharmaceuticals, Inc.

$3B

Q2 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$15M-30.6% YoY

Gross Profit

$15M96.6% margin

Operating Income

-$5M-34.2% margin

Net Income

-$6M-37.6% margin

EPS (Diluted)

$-0.24

QoQ Revenue Growth

+2734.3%

Cash Flow

Operating Cash Flow

-$4M

Free Cash Flow

-$4M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$253M

Total Liabilities

$31M

Stockholders' Equity

$222M

Cash & Equivalents

$245M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$15M	$22M	-30.6%
Gross Profit	$15M	$21M	-30.7%
Operating Income	-$5M	$7M	-171.7%
Net Income	-$6M	$6M	-191.2%

Revenue Segments

License and Service

$14M88%

Collaboration

$1M9%

License And Collaboration

$522,0003%

TARS Q2 2022 Earnings — Tarsus Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena